Related references
Note: Only part of the references are listed.GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796
Matthew F. McCown et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase
Stephanie T. Shi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
New Therapies for Hepatitis C Virus Infection
Vincent Soriano et al.
CLINICAL INFECTIOUS DISEASES (2009)
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
Christophe Hezode et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Identification of HCV protease inhibitor resistance mutations by selection pressure-based method
Ping Qiu et al.
NUCLEIC ACIDS RESEARCH (2009)
Characterization of resistance mutations against HCV ketoamide protease inhibitors
Xiao Tong et al.
ANTIVIRAL RESEARCH (2008)
Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors
Ann D. Kwong et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Naturally Occurring Dominant Resistance Mutations to Hepatitis C Virus Protease and Polymerase Inhibitors in Treatment-Naive Patients
Thomas Kuntzen et al.
HEPATOLOGY (2008)
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults
J. K. Rockstroh et al.
HIV MEDICINE (2008)
Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?
Vincent Soriano et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients
Sophie Le Pogam et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3•4A protease inhibitors in treatment-naive subjects
Doug J. Bartels et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN α-2b using TaqMan mismatch amplification mutation assay
Stephanie Curry et al.
JOURNAL OF VIROLOGICAL METHODS (2008)
Phenotypic characterization of resistant Val(36) variants of hepatitis C virus NS3-4A serine protease
Yi Zhou et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients
Tara L. Kieffer et al.
HEPATOLOGY (2007)
Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C
Nicole Forestier et al.
HEPATOLOGY (2007)
Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants -: Sensitivity to telaprevir (VX-950) and interferon α
Yi Zhou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034
Xiao Tong et al.
ANTIVIRAL RESEARCH (2006)
Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor - Reduced rna replication fitness and partial rescue by second-site mutations
MK Yi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Prospective multicenter study of eligibility for antiviral therapy among 4,084 US veterans with chronic hepatitis C virus infection
EJ Bini et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay
SW Ludmerer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven
GM Lucas
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Immunology of hepatitis B virus and hepatitis C virus infection
B Rehermann et al.
NATURE REVIEWS IMMUNOLOGY (2005)
In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061 - Structural analysis indicates different resistance mechanisms
C Lin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Mechanisms of disease: Hepatitis B virus infection - Natural history and clinical consequences
D Ganem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose
SJ Hadziyannis et al.
ANNALS OF INTERNAL MEDICINE (2004)
A long-term latent reservoir for HIV-1: discovery and clinical implications
JD Siliciano et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2004)
An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus
D Lamarre et al.
NATURE (2003)
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
MW Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
MP Manns et al.
LANCET (2001)
Share Paper
